Prescribing Information NAPROSYN Tablets (naproxen NAPROSYN Tablets (naproxen 250mg per tablet)
NAPROSYN 500 Tablets (naproxen 500mg per tablet)
NAPROSYN Suspension (naproxen 25mg/ml)
NAPROSYN Suppositories (naproxen 500mg per suppository)
Uses: Rheumatoid arthritis, osteo-Uses: Rheumatoid arthritis, osteo-arthrosis, ankylosing spondylitis, acute gout and acute musculo-skeletal disorders.

Dosage: For rheumatoid arthritis, osteoarthrosis and ankylosing spondylitis: 500 mg to 1g daily taken in two doses at 12-hour intervals. High doses should be used with caution in the elderly. For acute

High doses should be used with caution in the elderly. For acute gout: 750mg at once, then 250mg every eight hours until the attack has passed. For juvenile arthritis in children over 5 years: 5 mg/kg body weight twice daily. For acute musculo-skeletal disorders: 500mg initially, then 250mg at 6-8 hour intervals as needed with a maximum daily dose after the first day of

intervals as needed with a maximum daily dose after the first day of 1250 mg.

Contra-indications: Active peptic ulceration. Hypersensitivity to naproxen or naproxen sodium formulations. Aspirin/anti-inflammatory-induced allergy.

Warnings, precautions, etc: Episodes of GI bleeding have been reported. Use with care in patients with a history of GI disease. Use with caution in patients with impaired renal or hepatic function. Monitor renal function and con-Monitor renal function and con-sider reducing dosage in patients where renal blood flow is compromised (e.g. as in extracellular volume depletion, cirrhosis of the liver, sodium restriction, congestive liver, sodium restriction, congestive heart failure, pre-existing renal disease) – some elderly patients may fall in this category. Use with caution in patients with asthma or allergic disease. Caution is required if any of the following is administered concurrently: hydantoins, anti-coagulants or highly protein-bound sulphonamides; frusemide; propranolol or other beta-blockers; lithium; probenecid; methotrexate. NAPROSYN decreases platelet aggregation and methotrexate. NAPROSYN decreases platelet aggregation and prolongs bleeding time. Its use in pregnant or breast-feeding women should be avoided if possible.

Side-effects: GI-anusea, vomiting, pain; occasionally bleeding and ulceration. Dermatological/hypersensitivity – skin rashes, urticaria, angio-oedema; rarely anaphylactic reactions and eosinophilic pneumonits. CNS – headache, insomnia. inability to concentrate.

pneumonitis. CNS – headache, insomnia, inability to concentrate, cognitive dysfunction. Hoematological – thrombocytopenia, granulocytopenia, aplastic anaemia, haemolytic anaemia. Other – tinnitus, hearing impairment, vertigo, mild peripheral oedema (patients with compromised cardiac function may be at a greater risk on NAPROSYN): rarely jaundice, fatal hepatitis, nephropathy and ulcerative

rarely jaundice, tatal hepatitis, nephropathy and ulcerative stomatitis. Naprosyn Suppositories (local) – rectal discomfort, soreness, burning, itching, rectal bleeding, tenesmus, proctitis.

Basic NHS Cost: Tablets 250 mg £6.51 for 60 tablets, £25.98 for 250 tablets. Tablets 500 mg £20.78 for 100 tablets. Suspension £7.05 for


100 tablets. Suspension £7.05 for 500ml. Suppositories £2.53 for 10


Suppositories.

Product Licence No.:
PL 0286/0031 – Tablets (250 mg).
PL 0286/0061 – Tablets (500 mg).
PL 0286/0047 – Suspension.
PL 0286/0053 – Suppositories.



Further information is available from: SYNTEX Pharmaceuticals Limited, St. Ives Road, Maidenhead, Berks. SL6 1RD. *NAPROSYN is a trademarl







Prescribing Notes for 'Kalten', 'Tenormin' and Tenormin' LS

Hypertension 'Kalten' - 50 mg atenolo! + 25 mg hydrochlorothiazide + 2.5 mg amilloride hydrochloride (as amiloride hydrochloride BP 2.84 mg) orally one capsule daily; recommended where monotherapy with beta-blocker or diuretic proves inadequate.

Tenormin' - 100 mg atenolol, orally once a day. 'Tenormin' LS - 50 mg atenolol orally once a day; some patients may respond adequately to 'Tenormin' low strength (LS) **Children** – 'Kalten', 'Tenormin' and 'Tenormin' LS are not

recommended for use in children. **Elderly patients** – Dosage requirements for 'Tenormin' and 'Tenormin' LS may be lower, especially in patients with renal impairment.

'Kalten' may be suitable for older patients CONTRA-INDICATIONS

Kalten' : Heart block, hyperkalaemia, anuria, acute renal failure, severe progressive renal disease, diabetic nephropathy; blood urea over 10 mmol/I or serum creatinine over 130 micromol/Lif not possible to monitor carefully and frequently. In renal impairment additional potassium conserving agents may cause hyperkalaemia Sensitivity to hydrochlorothiazide or amiloride hydrochloride

PRECAUTIONS

Untreated cardiac failure, bradycardia, renal failure, anaesthesia, pregnancy Disturbed fluid or electrolyte balance. Caution in patients with chronic obstructive airways disease or asthma. Atenolol modifies the tachycardia of hypoglycaemia. Co-administration with verapamil or Class I antidysrhythmic agents. Withdrawal of clonidine

Withdrawal of beta-blocking drugs should be gradual in patients with ischaemic heart disease

Additional precautions for 'Kalten'

Co-administration with fithium.

Metabolic effects: Measurement of potassium levels is appropriate especially in the older patient, those receiving digitalis preparations for cardiac failure, taking adnormal (low in potassium) diet or suffering from gastrointestinal complaints.

Caution in metabolic or respiratory acidosis. Diabetes: 'Kalten' may lower glucose tolerance

Discontinue before glucose tolerance testing. Hyponatraemia and hypochloraemia may occur Hepatic or renal impairment: Caution in patients

where fluid and electrolyte balance is critical Hyperkalaemia and hypokalaemia may occur. Discontinue treatment if increasing azotaemia and oliguria occur. Amilloride may precipitate hepatic encephalopathy. Jaundice may occur in cirrhotic patients.

Breast-feeding: Discontinue if 'Kalten' deemed

SIDE EFFECTS

Coldness of extremities, bradycardia and muscular fatigue may occur. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta-blockers - consider discontinuance if they occur.

With amiloride hydrochloride and hydrochlorothiazide gastrointestinal disturbances may occur. Side-effects commonly associated with diuresis, dizziness and headache, may occur.

Skin rashes and blood dyscrasias have been reported.

PRODUCT LICENCE NUMBERS AND BASIC NHS

'Kalten' Capsules (29/186) in calendar packs of 28, £6.70. 'Tenormin' Tablets (29/122) in calendar packs of 28, £6.98. 'Tenormin' LS Tablets (29/86) in calendar packs of 28, £4.88

'Kalten', 'Tenormin' and 'Tenormin' LS are trade marks.

Further information is available on request from the Company



Stuart Pharmaceuticals Limited Stuart House, 50 Alderley Road, Wilmslow, Cheshire SK9 1RE

combines low strength 'Tenormin' with low dose amiloride/ hydrochlorothiazide.

1 One capsule daily Low dose

Cardioprotection Potassium protection

is the modern combination for patients uncontrolled on a diuretic alone.

en de la completa de la co

Service and reaction

One way of prescribing generics with confidence is with the traction leads that the marketing company has a reputation for quality products, high manufacturing standards and a commitment to research and development:

Ox Circular Ser Street Company and part of the largest Plannacator at Group is the UK

Tre killal angest 6x products meets name of the prescription needs of Doctors.

i ang kapagan Ungkambagan Pap. Kalang ng Panggang Panggan r (Arvin gundens) (7 11) Tesa (a 7) delle (2 50 iu ex egyenia en

That way you get the "

sound of the assurance strand name in page."

Mich & vay ne say: 14411. Commercial Robot (Microsov)

For a different information.